| Literature DB >> 28323835 |
Chanin Hatthakaroon1, Sujiraphong Pharkjaksu1, Piriyaporn Chongtrakool1, Kamol Suwannakarn1, Pattarachai Kiratisin1, Popchai Ngamskulrungroj1.
Abstract
Despite the strong association between Cryptococcus neoformans infection and the Human immunodeficiency virus (HIV) status of patients globally, most cryptococcosis cases in Far East Asia occur in non-HIV individuals. Molecular epidemiological studies, using multilocus sequence typing (MLST), have shown that more than 95% of cryptococcal strains belong to a specific subtype of VNI. However, this association has never been specifically examined in other parts of Asia. Therefore, in this study, we investigated the VNIc/ST5 genotype distribution among cryptococcosis patients in Thailand. Fifty-one C. neoformans isolates were collected from clinical samples in Siriraj Hospital, Bangkok, Thailand. The strains were predominantly isolated from HIV-positive patients (88.57%) and all were molecular type VNI MATα. An MLST analysis identified five sequence types (ST) in Siriraj Hospital, of which ST4 (45.10%) and ST6 (35.29%) were most common, and ST5 (15.69%), ST32 (1.96%), and ST93 (1.96) were less common. Contrary to reports from Far East Asia, ST5 was predominantly (83.33%) found in HIV patients (P = 0.657), and there was no significant change in the prevalence of ST5 over the past 10 years (P = 0.548). A further analysis of comorbidities showed higher morbidity and delays in the cryptococcal diagnosis in patients with tuberculosis coinfection or without HIV. Our study suggests that although the Thai population is genetically closely related to the Far East Asian population, ST5 is not associated with non-HIV status in Thailand. Therefore, this association may not be related to the host's genetic background. However, its mechanism remains unclear.Entities:
Mesh:
Year: 2017 PMID: 28323835 PMCID: PMC5360237 DOI: 10.1371/journal.pone.0173744
Source DB: PubMed Journal: PLoS One ISSN: 1932-6203 Impact factor: 3.240
Characteristics of C. neoformans isolated from patients.
| Characteristics | Count (%) |
|---|---|
| • Cerebrospinal fluid | 29 (56.86%) |
| • Blood | 21 (41.18%) |
| • Bone marrow | 1 (1.96%) |
| • 0–15 years | 0 |
| • 15–60 years | 29 (82.86%) |
| • >60 years | 6 (17.14%) |
| • Male | 23 (65.71%) |
| • Female | 12 (34.29%) |
| • Positive | 31 (88.57%) |
| • Negative | 4 (11.43%) |
Alleles and sequence types of the cryptococcal isolates in this study.
| Strain | Isolation site | HIV status | Molecular type | Mating type | Allelic profiles | ST | ||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| IGS1 | ||||||||||||
| SICN_001 | CSF | + | VNI | α | 1 | 3 | 1 | 5 | 2 | 1 | 1 | 5 |
| SICN_002 | Blood | - | VNI | α | 1 | 1 | 1 | 4 | 2 | 1 | 5 | 4 |
| SICN_003 | Blood | + | VNI | α | 1 | 1 | 1 | 3 | 2 | 1 | 5 | 6 |
| SICN_004 | CSF | + | VNI | α | 1 | 1 | 1 | 4 | 2 | 1 | 5 | 4 |
| SICN_005 | Blood | + | VNI | α | 1 | 1 | 1 | 4 | 2 | 1 | 5 | 4 |
| SICN_006 | Blood | + | VNI | α | 1 | 1 | 1 | 4 | 2 | 1 | 5 | 4 |
| SICN_008 | Blood | - | VNI | α | 1 | 1 | 1 | 3 | 2 | 1 | 5 | 6 |
| SICN_009 | CSF | - | VNI | α | 1 | 1 | 1 | 3 | 2 | 1 | 5 | 6 |
| SICN_011 | Blood | + | VNI | α | 1 | 1 | 1 | 4 | 2 | 1 | 5 | 4 |
| SICN_012 | CSF | + | VNI | α | 1 | 3 | 1 | 5 | 2 | 1 | 1 | 5 |
| SICN_013 | Blood | + | VNI | α | 1 | 1 | 1 | 4 | 2 | 1 | 5 | 4 |
| SICN_014 | CSF | + | VNI | α | 1 | 1 | 1 | 4 | 2 | 1 | 5 | 4 |
| SICN_015 | CSF | + | VNI | α | 1 | 1 | 1 | 3 | 2 | 1 | 5 | 6 |
| SICN_017 | Blood | + | VNI | α | 1 | 1 | 1 | 4 | 2 | 1 | 5 | 4 |
| SICN_018 | CSF | + | VNI | α | 1 | 23 | 10 | 3 | 4 | 1 | 1 | 93 |
| SICN_019 | CSF | + | VNI | α | 1 | 3 | 1 | 5 | 2 | 1 | 1 | 5 |
| SICN_021 | Blood | - | VNI | α | 1 | 3 | 1 | 5 | 2 | 1 | 1 | 5 |
| SICN_022 | Blood | U | VNI | α | 1 | 1 | 1 | 3 | 2 | 1 | 5 | 6 |
| SICN_024 | Blood | + | VNI | α | 1 | 1 | 1 | 3 | 2 | 1 | 5 | 6 |
| SICN_025 | CSF | - | VNI | α | 1 | 1 | 1 | 3 | 2 | 1 | 5 | 6 |
| SICN_026 | Blood | + | VNI | α | 1 | 1 | 1 | 3 | 2 | 1 | 5 | 6 |
| SICN_027 | CSF | + | VNI | α | 1 | 1 | 1 | 3 | 2 | 1 | 5 | 6 |
| SICN_028 | CSF | + | VNI | α | 1 | 3 | 1 | 5 | 2 | 1 | 1 | 5 |
| SICN_029 | CSF | - | VNI | α | 1 | 1 | 1 | 3 | 2 | 1 | 5 | 6 |
| SICN_030 | Blood | + | VNI | α | 1 | 3 | 1 | 5 | 2 | 1 | 1 | 5 |
| SICN_031 | Blood | + | VNI | α | 1 | 1 | 1 | 3 | 2 | 1 | 5 | 6 |
| SICN_032 | CSF | + | VNI | α | 1 | 1 | 1 | 4 | 2 | 1 | 5 | 4 |
| SICN_033 | Blood | + | VNI | α | 1 | 1 | 1 | 3 | 2 | 1 | 5 | 6 |
| SICN_034 | Bone marrow | - | VNI | α | 1 | 1 | 1 | 3 | 2 | 1 | 5 | 6 |
| SICN_035 | CSF | + | VNI | α | 1 | 1 | 1 | 4 | 2 | 1 | 5 | 4 |
| SICN_036 | CSF | + | VNI | α | 1 | 1 | 1 | 4 | 2 | 1 | 5 | 4 |
| SICN_038 | CSF | + | VNI | α | 1 | 1 | 1 | 4 | 2 | 1 | 5 | 4 |
| SICN_039 | CSF | - | VNI | α | 1 | 1 | 1 | 4 | 2 | 1 | 5 | 4 |
| SICN_040 | CSF | + | VNI | α | 1 | 1 | 1 | 4 | 2 | 1 | 5 | 4 |
| SICN_041 | CSF | + | VNI | α | 1 | 1 | 10 | 3 | 4 | 1 | 1 | 32 |
| SICN_060 | Blood | U | VNI | α | 1 | 1 | 1 | 4 | 2 | 1 | 5 | 4 |
| SICN_061 | CSF | U | VNI | α | 1 | 1 | 1 | 3 | 2 | 1 | 5 | 6 |
| SICN_062 | CSF | U | VNI | α | 1 | 1 | 1 | 4 | 2 | 1 | 5 | 4 |
| SICN_063 | CSF | U | VNI | α | 1 | 1 | 1 | 3 | 2 | 1 | 5 | 6 |
| SICN_064 | Blood | U | VNI | α | 1 | 1 | 1 | 4 | 2 | 1 | 5 | 4 |
| SICN_065 | CSF | U | VNI | α | 1 | 1 | 1 | 4 | 2 | 1 | 5 | 4 |
| SICN_066 | Blood | U | VNI | α | 1 | 1 | 1 | 4 | 2 | 1 | 5 | 4 |
| SICN_067 | CSF | U | VNI | α | 1 | 1 | 1 | 4 | 2 | 1 | 5 | 4 |
| SICN_068 | CSF | U | VNI | α | 1 | 1 | 1 | 4 | 2 | 1 | 5 | 4 |
| SICN_069 | CSF | + | VNI | α | 1 | 1 | 1 | 4 | 2 | 1 | 5 | 4 |
| SICN_070 | CSF | U | VNI | α | 1 | 3 | 1 | 5 | 2 | 1 | 1 | 5 |
| SICN_071 | CSF | U | VNI | α | 1 | 1 | 1 | 3 | 2 | 1 | 5 | 6 |
| SICN_072 | Blood | U | VNI | α | 1 | 1 | 1 | 4 | 2 | 1 | 5 | 4 |
| SICN_073 | Blood | U | VNI | α | 1 | 1 | 1 | 3 | 2 | 1 | 5 | 6 |
| SICN_074 | Blood | U | VNI | α | 1 | 3 | 1 | 5 | 2 | 1 | 1 | 5 |
| SICN_075 | CSF | U | VNI | α | 1 | 1 | 1 | 3 | 2 | 1 | 5 | 6 |
U = Unknown, CSF = Cerebrospinal fluid, ST = sequence type
Fig 1Phylogram of the C. neoformans isolates.
Phylogram depicting the genetic relationships between the C. neoformans isolates based on neighbor joining analysis of the concatenated seven ISHAM consensus MLST loci using the program MEGA 6.06.
Association between sequence types, HIV status, and time.
| Data | Sequence type | P-value | ||
|---|---|---|---|---|
| ST5 | Non-ST-5 | |||
| Positive (n = 31) | 5 (16.13%) | 26 (83.87%) | 0.657 | |
| Negative (n = 4) | 1 (25.00%) | 3 (75.00%) | ||
| 2003–2005 (n = 231) | 29 (12.55%) | 201 (87.45%) | 0.548 | |
| 2012–2014 (n = 51) | 8 (15.70%) | 43 (84.30%) | ||
#only data available in medical records were considered
Association between comorbidity (HIV or TB) and treatment outcome#.
| Disease | Treatment outcome | P-value | ||
|---|---|---|---|---|
| Cure | Death | |||
| Active (n = 4) | 1 (25.00%) | 3 (75.00%) | 0.031 | |
| Non active (n = 27) | 18 (78.26%) | 5 (21.74%) | ||
| Positive (n = 22) | 17 (77.27%) | 5 (22.73%) | 0.041 | |
| Negative (n = 6) | 2 (33.33%) | 4 (66.67%) | ||
#only data available in medical records were considered.
Association between comorbidity (HIV or TB) and time from symptom onset to disease diagnosis.
| Disease | Mean of time from symptom onset to disease diagnosis (days) | P-value | |
|---|---|---|---|
| Active/positive status | Non-active/negative status | ||
| 42.50 (n = 4) | 22.35 (n = 31) | 0.401 | |
| 18.74 (n = 27) | 44.63 (n = 8) | 0.024 | |
#only data available in medical records were considered.